Skip to main content

Financial Statements

Notes 16-20

19 PROVISIONS FOR LIABILITIES AND CHARGES

Severence
$m
Environmental
$m
Employee
benefits
$m
Other
provisions
$m
Total
$m
At 1 January 2005 34 67 121 83 305
Charge for the year 33 17 32 20 102
Cash paid (1) (16) (20) (37)
Exchange and other movements (4) (11) (1) (16)
At 31 December 2005 62 68 122 102 354
Charge/(credit) for the year (1) 56 36 (4) 87
On acquisition of subsidiary 20 20
Cash paid (36) (29) (36) (5) (106)
Exchange and other movements 6 (13) 18 11
At 31 December 2006 31 95 109 131 366
Charge for the year 620 48 4 58 730
Cash paid (25) (32) (23) (25) (105)
Exchange and other movements 17 10 2 29
At 31 December 2007 643 111 100 166 1,020
2007
$m
2006
$m
2005
$m
Due within one year 387 39 45
Due after more than one year 633 327 309
1,020 366 354

AstraZeneca is undergoing a worldwide restructuring initiative which involves rationalisation of the Global Supply Chain, European Sales and Marketing, Information Services and Business Support infrastructure and Research and Development. Employee costs in connection with the initiatives are recognised in severance provisions. This is a three-year programme expected to be substantially completed by the end of 2009.

Employee benefit provisions include the executive deferred bonus plan and other employee benefit provisions. Further details are included in Note 26.

Details of environmental and litigation provisions are provided in Note 27.

No provision has been released or applied for any purpose other than that for which it was established.

Back to top ↑